Selexipag-based Triple Combination Therapy Improves Prognosis in Chinese Pulmonary Arterial Hypertension Patients

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2022 Oct 7

PMID 36204579

Authors

Xiaopei Cui

Weida Lu

Deyuan Zhang

Liangyi Qie

Haijun Li

Xiao Li

Hui Liu

Qiushang Ji

Affiliations

Soon will be listed here.

Abstract

Aim: Selexipag is an oral selective prostacyclin receptor agonist approved for treatment of patients with pulmonary arterial hypertension (PAH). In the present study, we aim to assess the safety and efficacy of selexipag in triple combination therapy with endothelial receptor antagonists (ERAs) and PDE5is for Chinese PAH patients.

Methods And Results: A single center retrospective study was performed on group 1 PAH patients ( = 68) initiating triple combination therapy with selexipag from 1 February 2020 to 31 August 2021 in Qilu Hospital of Shandong University (Shandong, China). Adolescents, children, and PAH patients with unrepaired congenital heart disease were excluded. The French pulmonary hypertension network (FPHN) non-invasive risk assessment, echocardiogram parameters, and clinical data, including tolerability, safety, and death/hospitalization events associated with PAH, were collected. Of the 68 patients, 31 (45.6%) patients had tolerable side effects while only a single patient discontinued selexipag due to severe diarrhea. In the analysis of the efficacy set of 62 patients, the median selexipag treatment time from selexipag initiation to last risk assessment was 27 (21, 33) weeks. Compared to baseline parameters, the percentage of WHO FC III/IV decreased from 77.4% (48) to 24.2% (15) ( = 0.000), median 6-min walk distance (6MWD) increased 82 m [from 398 (318, 450) to 480 (420, 506) m; = 0.000], and NT-proBNP levels decreased from 1,216 (329, 2,159) to 455 (134, 1,678) pg/mL ( = 0.007). Patients who improved to three low-risk criteria increased from 9.7 to 38.7%. Right ventricular diameter (RV) diameter also decreased and was accompanied by an improved tricuspid annular plane systolic excursion (TAPSE). Patients transitioning from subcutaneous treprostinil to selexipag continued to show improvements in WHO FC, 6MWD (404 ± 94 vs. 383 ± 127 m) and NT-proBNP levels (2,319 ± 2,448 vs. 2,987 ± 3,770 pg/mL). Finally, the 1-year event free survival rate was 96.7% for patients initiating the triple combination therapy within 3 years of PAH diagnosis.

Conclusion: Triple combination therapy with selexipag was safe and effective in Chinese PAH patients, which was confirmed by acceptable tolerability, and improved exercise capacity, right heart function, risk assessment, and prognosis.

Citing Articles

Prognostic Value of Serial Risk Stratification in Adult and Pediatric Pulmonary Arterial Hypertension: A Systematic Review.

Lokhorst C, van der Werf S, Berger R, Douwes J J Am Heart Assoc. 2024; 13(13):e034151.

PMID: 38904230 PMC: 11255703. DOI: 10.1161/JAHA.123.034151.

Oral Prostacyclin Pathway Agents Used in PAH: A Targeted Literature Review.

Burger C, Tsang Y, Chivers M, Vekaria R, Doad G, Atkins N Clinicoecon Outcomes Res. 2024; 16:447-459.

PMID: 38831921 PMC: 11146608. DOI: 10.2147/CEOR.S460912.

Evaluating the efficacy and safety of oral triple sequential combination therapy for treating patients with pulmonary arterial hypertension: A multicenter retrospective study.

Zhao Q, Chen J, Chen F, Ruan H, Zhang W, Zhou Y Pulm Circ. 2024; 14(1):e12351.

PMID: 38468630 PMC: 10925724. DOI: 10.1002/pul2.12351.

Impact of different sequential triple oral combination therapies based selexipag on outcomes in pulmonary arterial hypertension.

Hu X, Yuan P, Chen J, Wang S, Zhao H, Wei Y Clin Cardiol. 2024; 47(2):e24245.

PMID: 38402556 PMC: 10894617. DOI: 10.1002/clc.24245.

References

Simonneau G, Barst R, Galie N, Naeije R, Rich S, Bourge R . Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002; 165(6):800-4. DOI: 10.1164/ajrccm.165.6.2106079. View

Barnikel M, Kneidinger N, Klenner F, Waelde A, Arnold P, Sonneck T . Real-life data on Selexipag for the treatment of pulmonary hypertension. Pulm Circ. 2019; 9(1):2045894019832199. PMC: 6381437. DOI: 10.1177/2045894019832199. View

Hoeper M, McLaughlin V, Barbera J, Frost A, Ghofrani H, Peacock A . Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respir Med. 2016; 4(11):894-901. DOI: 10.1016/S2213-2600(16)30307-1. View

Kylhammar D, Kjellstrom B, Hjalmarsson C, Jansson K, Nisell M, Soderberg S . A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2017; 39(47):4175-4181. DOI: 10.1093/eurheartj/ehx257. View

DAlto M, Badagliacca R, Giudice F, Argiento P, Casu G, Corda M . Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension. J Heart Lung Transplant. 2020; 39(12):1389-1397. DOI: 10.1016/j.healun.2020.08.016. View

Ghosh R, Ball S, Das A, Bandyopadhyay D, Mondal S, Saha D . Selexipag in Pulmonary Arterial Hypertension: Most Updated Evidence From Recent Preclinical and Clinical Studies. J Clin Pharmacol. 2016; 57(5):547-557. DOI: 10.1002/jcph.834. View

Kim N, Hemnes A, Chakinala M, Highland K, Chin K, McLaughlin V . Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE. J Heart Lung Transplant. 2021; 40(4):279-288. DOI: 10.1016/j.healun.2021.01.006. View

Ghofrani H, Galie N, Grimminger F, Grunig E, Humbert M, Jing Z . Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013; 369(4):330-40. DOI: 10.1056/NEJMoa1209655. View

Hoeper M, Pittrow D, Opitz C, Gibbs J, Rosenkranz S, Grunig E . Risk assessment in pulmonary arterial hypertension. Eur Respir J. 2018; 51(3). DOI: 10.1183/13993003.02606-2017. View

10.

Liu K, Zhang C, Chen B, Li M, Zhang P . Association between right atrial area measured by echocardiography and prognosis among pulmonary arterial hypertension: a systematic review and meta-analysis. BMJ Open. 2020; 10(9):e031316. PMC: 7509969. DOI: 10.1136/bmjopen-2019-031316. View

11.

Marra A, Halank M, Benjamin N, Bossone E, Cittadini A, Eichstaedt C . Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study). Respir Res. 2018; 19(1):258. PMC: 6299931. DOI: 10.1186/s12931-018-0957-y. View

12.

Coghlan J, Channick R, Chin K, Di Scala L, Galie N, Ghofrani H . Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. Am J Cardiovasc Drugs. 2018; 18(1):37-47. PMC: 5772136. DOI: 10.1007/s40256-017-0262-z. View

13.

Parikh K, Doerfler S, Shelburne N, Kennedy K, Whitson J, Dahhan T . Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension. J Cardiovasc Pharmacol. 2020; 75(4):299-304. DOI: 10.1097/FJC.0000000000000800. View

14.

Galie N, Palazzini M, Manes A . Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J. 2010; 31(17):2080-6. PMC: 2930983. DOI: 10.1093/eurheartj/ehq152. View

15.

Kozu K, Sugimura K, Ito M, Hirata K, Node K, Miyamoto T . Current status of long-term prognosis among all subtypes of pulmonary hypertension in Japan. Int J Cardiol. 2019; 300:228-235. DOI: 10.1016/j.ijcard.2019.11.139. View

16.

Boucly A, Weatherald J, Savale L, Jais X, Cottin V, Prevot G . Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017; 50(2). DOI: 10.1183/13993003.00889-2017. View

17.

Humbert M, Sitbon O, Yaici A, Montani D, OCallaghan D, Jais X . Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010; 36(3):549-55. DOI: 10.1183/09031936.00057010. View

18.

Sitbon O, Channick R, Chin K, Frey A, Gaine S, Galie N . Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373(26):2522-33. DOI: 10.1056/NEJMoa1503184. View

19.

Chin K, Sitbon O, Doelberg M, Feldman J, Gibbs J, Grunig E . Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2021; 78(14):1393-1403. DOI: 10.1016/j.jacc.2021.07.057. View

20.

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Heart J. 2015; 37(1):67-119. DOI: 10.1093/eurheartj/ehv317. View